Cyanatx
Cyana Therapeutics develops precision immuno-oncology drugs targeting solid tumors. The company's lead compound, CY-3132, is a small molecule inhibitor designed to block the ENPP1 enzyme expressed on tumor cells. By inhibiting ENPP1, the therapy aims to restore cancer cell immune signaling, making tumors susceptible to the body's immune response.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Cyana Therapeutics develops precision immuno-oncology drugs targeting solid tumors. The company's lead compound, CY-3132, is a small molecule inhibitor designed to block the ENPP1 enzyme expressed on tumor cells. By inhibiting ENPP1, the therapy aims to restore cancer cell immune signaling, making tumors susceptible to the body's immune response.